Friday, August 28, 2015
QB3@953, a full-service San Francisco incubator for life science startups created by QB3, a University of California research institute and biotech accelerator, has inked an agreement with GlaxoSmithKline to identify and facilitate collaborations to translate early drug target concepts into medicines that benefit patients.
Genentech has initiated a phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus vulgaris (PV), a rare, chronic and potentially fatal, blistering skin disease. The aim of the study, called PEMPHIX, is to determine the efficacy and safety of Rituxan for the treatment of PV. The current standard-of-care includes high doses of corticosteroids taken for several weeks and corticosteroids in combination with the off-label use of corticosteroid-sparing immunosuppressive drugs for many months, which can cause significant, long-term side effects.
Amneal Pharmaceuticals has launched Amneal Biosciences, a wholly owned subsidiary. Amneal Biosciences will focus exclusively on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics and biosimilars to healthcare providers globally.
Scientists at Heilbronn, Germany-based Greenovation Biotech and Dallas-based Baylor Research Institute have published results from a preclinical study in Fabry mice in the Journal of Inherited Metabolic Diseases. Results of the study imply that replacement enzymes exhibiting mannose-terminated glycosylation patterns are efficiently delivered to their subcellular targets, the lysosomes.
Becton, Dickinson and Company (BD) has completed its acquisition of Cellular Research, a biotechnology R&D company. Cellular Research has developed advanced tools for massively parallel single cell genetic analysis based on their proprietary molecular indexing technology to enable gene expression profiles from single cells.
Life sciences organizations typically implement cross-functional brand commercialization committees to drive product development and maximize commercial success, according to a new study by pharmaceutical intelligence firm Cutting Edge Information. Those groups often are tasked with making key brand strategy decisions and with coordinating a broad range of brand activities throughout the product lifecycle.
Enumeral Biomedical Holdings has entered into a research study agreement with University of Massachusetts Medical School, which includes the institution’s clinical partner, UMass Memorial HealthCare. UMass Medical will provide Enumeral with tissue samples and blood samples from subjects with melanoma who are being treated with Ipilimumab (Yervoy). Enumeral will fund the tissue collection activities, and Enumeral will have access to the samples for research-only use in in-vitro studies.